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Immune responses to human melanoma have 
been extensively studied, and various immuno-
therapies have been developed (1–4). One of 
the major problems contributing to immuno-
logical rejection of cancer is immune evasion 
through various mechanisms (5). Immune eva-
sion is one of the malignant phenotypes that 
allows cancer cells to survive in the host. It is 
important to understand the molecular mecha-
nisms of immune evasion to allow the develop-
ment of cancer immunotherapy. Most cancer 
cells produce several immune suppressive factors 
that allow them to evade the host immune sys-
tem (6, 7). The mechanisms for the production 
of these eff  ector molecules in cancer cells have 
not been investigated well, although oncogenic 
STAT3 signaling has recently been reported 
to result in immune evasion through produc-
tion of immune suppressive factors in various 
murine cancers (8, 9). In this study, we have 
evaluated the role of mitogen-activated protein 
kinase (MAPK) signaling in the production of 
various immune-suppressive cytokines. MAPK 
activation occurs frequently in human cancers 
due to various genetic changes, and MAPK 
signaling is also important in the regulation 
of cytokine signal pathways. Using a MAPK 
inhibitor and lentiviral BRAFV600E RNA in-
terference (RNAi), we demonstrated that the 
MAPK pathway, along with STAT3 pathway 
signaling, is essential for production of immu-
nosuppressive factors by human melanoma cells 
that have constitutively activated MAPK signal-
ing due to the BRAFV600E mutation, which is 
detected in 66% of melanomas (10).
RESULTS AND DISCUSSION
An A375 melanoma cell line with a constitu-
tively activated MAPK due to a BRAFV600E 
mutation was treated with MEK inhibitor 
U0126 at a concentration of 25 μM for 8 h,
resulting in the suppression of the ERK 
phosphorylation (Fig. 1 a). Immune-suppres-
sive soluble factor mRNAs, including IL-6, 
IL-10, and VEGF, signifi  cantly decreased with 
the U0126 treatment (Fig. 1 b), whereas the 
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control DMSO treatment did not aff  ect the production of 
IL-10 and VEGF mRNAs, and only slightly increased the 
level of IL-6 mRNA. An 18-h exposure to U0126 also sup-
pressed the production of IL-10, VEGF, and IL-6 at the pro-
tein level, indicating that activated ERKs may be responsible 
for suppressing local immune responses against melanoma by 
producing these immunosuppressive factors (Fig. 1 c). In ad-
dition, the suppression of ERK phosphorylation and the in-
hibition of IL-6, IL-10, and VEGF production occurred even 
after reducing the concentration of the U0126 treatment to 
10 μM (not depicted). During this study, no signifi  cant cy-
totoxic eff  ects were observed with the U0126 treatment of 
the A375 cells. Although U0126 is known to inhibit MEK5 
in addition to MEK1/2, phosphorylated ERK5, the MEK5 
substrate, was not detected in the A375 cells (not depicted), 
indicating that the MEK1/2–ERK1/2 pathway is responsible 
for the eff  ects observed with U0126 treatment. The suppres-
sive eff  ects of U0126 on IL-10 and VEGF production were 
also demonstrated in three other melanoma cell lines with the 
BRAFV600E mutation, 624mel, 888mel, and 928mel, with-
out any signifi  cant cellular toxicity (Fig. 1 d). Because these 
melanoma cell lines do not produce IL-6, activated MAPK 
signaling appears to have a general role in the production of 
immunosuppressive factors IL-10 and VEGF in BRAFV600E
+ 
melanoma cell lines.
However, nonspecifi  c eff  ects of U0126 on the cytokine 
production via pathways other than the MAPK signaling can-
not be completely ruled out from these experiments because of 
the observed slight decrease in STAT3 phosphorylation at 
Ser727 in 888mel and 928mel (Fig. 1 d). To confi  rm the role 
of the activated MAPK due to the BRAFV600E mutation in the 
production of IL-10, VEGF, and IL-6, BRAFV600E-specifi  c 
Figure 1.  Decreased production of immunosuppressive soluble fac-
tors IL-6, IL-10, and VEGF from melanoma cell lines with constitu-
tively active MAPK through the BRAF V600E mutation by inhibition of 
the MAPK signaling with a MEK inhibitor, U0126. (a) Inhibition of 
phosphorylation of ERK1/2 was detected by Western blot analysis of the 
A375mel melanoma cell line with the BRAF V600E mutation before and 2, 4, 
6, and 8 h after treatment with MEK inhibitor U0126 at a concentration of 
25 μM. (b) Inhibition of mRNA expression for immunosuppressive soluble 
factors IL-6, IL-10, and VEGF in A375 cells. The mRNAs for various soluble 
factors, including IL-6, IL-10, and VEGF, were measured by quantitative RT-
PCR before and 2, 4, 6, and 8 h after the treatment with U0126. The con-
trol treatment was performed with a DMSO solution. The mRNA levels at 
each time point were normalized to GAPDH mRNA and indicated as the 
relative value to that of 0 h. (c) Decreased production of IL-6, IL-10, and 
VEGF proteins from A375 cells after an 18-h treatment with U0126 at a 
concentration of 25 μM. The expression was detected by ELISA with the 
culture supernatants. The ratio of viability of U0126-treated cells DMSO-
treated cells at the harvest was 77%. The cytokine production was normal-
ized to the value of control DMSO-treated cells based on the cell count. 
Western blot showed strong inhibition of ERK phosphorylation, but not of 
STAT3 protein, or its phosphorylation at Ser727 and Tyr705. (d) Decreased 
production of IL-10 and VEGF from three melanoma cell lines with the 
BRAF V600E mutation, 624mel, 888mel, and 928mel after an 18-h treatment 
with U0126 at a concentration of 25 μM, which was detected by ELISA 
with the culture supernatants. The ratios of viability of U0126-treated cells 
DMSO-treated cells at the harvest were 95% for 624mel, 103% for 
888mel, and 100% for 928mel. The cytokine production was normalized to 
the value of control DMSO-treated cells based on the cell count. Western 
blot showed strong inhibition of ERK phosphorylation, but not of STAT3 
protein. Slight decrease of Ser727 phosphorylation of STAT3 was observed 
in 888mel and 928mel cells, but not in 624mel cells. These results are rep-
resentative of three or four independent experiments with similar results.JEM VOL. 203, July 10, 2006  1653
BRIEF DEFINITIVE REPORT
RNAi was transfected into three melanoma cell lines, A375, 
888mel, and 624mel, using the lentivirus expressing BRAFV600E-
specifi  c short hairpin RNA (shRNA) (11). The BRAFV600E-
specifi  c RNAi signifi  cantly inhibited IL-10, VEGF, and IL-6 
production as well as suppressed ERK phosphorylation (Fig. 
2). These results confi  rm that the inhibition of these factors by 
U0126 (Fig. 1) is correlated with the specifi  c inhibition of the 
MAPK pathway. These results are consistent with recent pa-
pers showing ERK1/2-induced IL-10 production in murine 
macrophages (12) and BRAFV600E-dependent VEGF produc-
tion for promotion of angiogenesis (13).
Because activated STAT3 signaling has been determined 
to result in immune evasion from cancer through the pro-
duction of various factors including VEGF (8, 9), we inves-
tigated the relationship between the MAPK and the STAT3 
pathways concerning the production of immunosuppressive 
factors in the A375 melanoma cell line. The production of 
IL-6, IL-10, and VEGF was profoundly inhibited by RNAi 
targeting either BRAFV600E alone or STAT3 alone (Fig. 3 a). 
No clear additive or synergistic eff  ect was observed by si-
multaneously restricting the BRAF–MAPK and STAT3 
pathways (Fig. 3 a). BRAFV600E RNAi in the A375 cells did 
not decrease the STAT3 DNA-binding activity (Fig. 3 b), 
the STAT3 promoter activity (Fig. 3 c), or STAT3 phos-
phorylation at either Ser727 or Tyr705 (Fig. 2), although ERKs 
were reported to be potentially able to phosphorylate STAT3 
at Ser727 (14). However, STAT3 phosphorylation can also 
occur by an ERK-independent pathway (15). In 624mel 
cells, although there was a slight decrease of Ser727-phos-
phorylated STAT3, DNA-binding activity (Fig. 3 b) and 
STAT3 promoter activity (Fig. 3 c) were not aff  ected by the 
BRAFV600E RNAi (Fig. 2). In 888mel cells, there was a simi-
lar decrease of Ser727 phosphorylation, but, conversely, both 
STAT3 DNA-binding activity (Fig. 3 b) and STAT3 pro-
moter activity (Fig. 3 c) decreased after the BRAFV600E 
RNAi (Fig. 2). These results suggest that the reduction in 
the STAT3 transcription activity is not the main mechanism 
generating the immunosuppressive factor suppression by the 
down-regulation of the MAPK signaling in these melanoma 
cell lines.
Figure 2.  Decreased production of immunosuppressive factors 
IL-6, IL-10, and VEGF from three melanoma cell lines with the 
BRAF V600E mutation by BRAF V600E-specifi  c RNAi. The three melanoma 
cell lines with the BRAF V600E mutation, A375mel, 888mel, and 624mel, 
were infected with the lentivirus vectors encoding short hairpin RNA for 
either fi  refl  y luciferase mRNA (GL3B; as control) or BRAF V600E mRNA 
(BRAF#1′) at 50 or 100 multiplicity of infection. At 5 or 6 d after the in-
fection, proteins were extracted and subjected to Western blot analysis. 
Profound decrease of phosphorylation of ERK1/2 with decrease of the 
BRAF protein was observed by the BRAF V600E-specifi  c RNAi. No signifi  cant 
difference in STAT3 protein and phosphorylation of STAT3 at Ser727 or 
Tyr705 was observed. A slight decrease of phosphorylation at Ser727 was 
observed in 888mel and 624mel cells after BRAF RNAi. 5 or 6 d after the 
lentivirus infection, the equal number of the melanoma cells was dis-
pensed at a density of 1–2 × 106 cells/2 ml, and the culture supernatants 
after 18 h were subjected to ELISA for IL-6, IL-10, or VEGF. Profound de-
crease of IL-6, IL-10, and VEGF was observed. One representative result of 
two or three independent experiments with similar results is shown.1654  BRAF–MAPK-MEDIATED CANCER-IMMUNE EVASION | Sumimoto et al.
Next, the potential eff  ects caused by the soluble factors 
induced by the MAPK and STAT3 signaling in the superna-
tant of the A375 cultures upon the maturation of DCs were 
investigated. The supernatant from the cultured A375 mela-
noma cells contains soluble factors that inhibit human mono-
cyte-derived DC (MoDC) maturation when stimulated with 
Toll-like receptor ligands such as LPS. The addition of the 
A375 culture supernatants to MoDC cultures at a fi  nal con-
centration of 10–20% signifi  cantly decreased the production 
of infl  ammatory cytokines, including IL-12 and TNF-α, in 
MoDCs as well as CD1a and CD83 cellular surface mole-
cules, but not CD80, CD86, CD40, or HLA-DR on MoDCs. 
Figure 3.  Inhibition of IL-6, IL-10, and VEGF production in A375 
cells through the RNAi for BRAF V600E alone, STAT3 alone, or both, 
without signifi  cant changes in the DNA-binding and promoter ac-
tivity of STAT3. (a) Profound inhibition of IL-6, IL-10, and VEGF pro-
duction in A375 through the RNAi for BRAF V600E alone, STAT3 alone, or 
both. 5 or 6 d after the infection, the equal number of the cells was dis-
pensed at a density of 106 cells/2 ml, and the culture supernatant after 
18 h was subjected to ELISA for IL-6, VEGF, and IL-10. Decrease of BRAF 
and phosphorylated ERK1/2 by the BRAF V600E-specifi  c RNAi and decrease 
of STAT3 by the STAT3-specifi  c RNAi were confi  rmed by Western blot 
analysis. One representative result of six independent experiments with 
similar results is shown. (b) No signifi  cant change of the STAT3 DNA-
binding activity by the inhibition of MAPK signaling with BRAF RNAi in 
melanoma cell lines. STAT3 DNA-binding activity was examined by EMSA 
of the nuclear extracts from melanoma cell lines with either control 
GL3B or BRAF#1′ shRNA vector treatment. Specifi  c STAT3 bands indi-
cated by arrows disappeared with cold wild-type STAT3 DNA probe (wt), 
but not with mutant STAT3 DNA probe (mt). Only a slight decrease of 
STAT3 DNA-binding activity was observed in 888mel cells. (c) STAT3 re-
porter assays in A375, 624mel, and 888mel cells. 2–4 × 105 cells with 
either control or BRAF#1′ shRNA vector infection were transfected with 
0.4 μg pSTAT3-TA-Luc and 0.4 μg pRL-SV40 with Effectene Transfection 
Reagent. 24 h after the transfection, the cells were harvested and ana-
lyzed for fi  refl  y and renilla luciferase activity. Each fi  refl  y luciferase ac-
tivity was normalized with the renilla luciferase activity. Shaded bars and 
error bars indicate the mean and standard deviation of the triplicate 
assays, respectively. One representative experiment of three or four inde-
pendent experiments is shown. STAT3-driven transcription was not 
changed after the BRAF RNAi in A375 and 624mel, but it slightly de-
creased in 888mel.JEM VOL. 203, July 10, 2006  1655
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Supernatants from the other three melanoma cell lines pro-
duced the same results when added to the MoDC cultures 
(not depicted). The suppressive activity of the melanoma cell 
supernatants stems from the production of IL-6, IL-10, and 
VEGF because the addition of specifi  c antibodies for these 
factors reduced the suppressive activity of the A375 culture 
supernatants (Fig. 4 a). Disparities between our observations 
and the previously reported results concerning murine B16 
melanoma cell supernatant with an activated STAT3 inhibit-
ing the expression of MHC class II and CD40 may be ex-
plained by diff  erent tumor cells or species (8).
The suppressive activity of the A375 culture supernatants 
on the IL-12 and TNF-α production of the LPS-treated 
MoDCs was restored by pretreating the A375 cells with ei-
ther RNAi targeting BRAFV600E alone, STAT3 alone, or 
both BRAFV600E and STAT3 (Fig. 4 b). Although the STAT3 
RNAi appeared to reduce the suppressive activity of the A375 
culture supernatants more than the BRAFV600E RNAi, the 
diff  erence may be simply caused by diff  erent RNAi activities. 
However, it is important to note that no additive and syner-
gistic eff  ects by the RNAi simultaneous-targeting BRAF and 
STAT3 were observed; again, indicating the essential roles of 
both signaling pathways in the production of suppressive fac-
tors on DC maturation. Although activation of DCs by the 
supernatant from murine CT26 colon cancer cell line trans-
fected with a dominant-negative form of STAT3 possibly 
through the increased production of proinfl  ammatory cyto-
kines had been reported, activation of DCs was not observed 
in this study. It may be explained by an incomplete inhibition 
of BRAF and STAT3, no augmented proinfl  ammatory cyto-
kine production in the BRAF shRNA-transfected melanoma 
cells, or by diff  erences in tumor cells or species.
In summary, we have demonstrated for the fi  rst time an 
essential role of the MAPK signaling along with the STAT3 
pathway on the production of various immunosuppressive 
factors in melanoma cell lines with constitutively active 
MAPK due to the common BRAFV600E mutation. Thus, the 
MAPK pathway may be a potentially signifi  cant molecular 
target for overcoming immune evasion of various cancers be-
cause it is frequently activated in several types of cancers, in-
cluding melanoma without BRAFV600E mutation (16, 17).
MATERIALS AND METHODS
Cell lines and reagents. A375, 624mel, 888mel, and 928mel were cul-
tured in RPMI 1640 media supplemented with 10% FBS, penicillin, and 
streptomycin. Stock solution of MEK inhibitor U0126 (Sigma-Aldrich) was 
made by dissolving the U0126 in DMSO.
Quantitative RT-PCR. RT-PCR was performed by using TaqMan PCR 
assay probe/primers (Assay-on-Demand, Gene Expression Products;   Applied 
Biosystems) for IL-6, IL-10, VEGF, and GAPDH by using ABI PRISM 
7900HT (Applied Biosystems), and a relative quantitative method was 
  applied for the target mRNA, which was normalized by the control 
GAPDH mRNA.
ELISA. Human VEGF, IL-6, IL-12, and TNF-α were measured by using 
the DuoSet ELISA Development System (R&D Systems), and human IL-10 
was measured by using the BD OptiEIA kit (BD Biosciences).
Figure 4.  Decreased suppressive activity of the A375 melanoma 
culture supernatants by pretreatment with RNAi for BRAF V600E 
alone, STAT3 alone, or both on LPS-induced IL-12 and TNF-𝗂 
production from DCs. (a) Neutralization of IL-6, IL-10, or VEGF in the 
culture supernatants of A375 melanoma cells restored the inhibition of 
IL-12 production from LPS-stimulated human DCs. Human MoDCs 
were cultured with the A375 supernatants in the presence or absence 
of the monoclonal antibody for IL-6, IL-10, VEGF, or an isotype control 
antibody at 1 μg/ml. IL-12 production in the culture supernatants was 
determined by ELISA 24 h after the LPS stimulation at 100 ng/ml. 
(b) CD14+ monocytes were isolated from PBMCs by using MACS and 
  cultured in the media containing RPMI 1640, 10% (vol/vol) FBS, 
100 ng/ml GM-CSF, and 50 ng/ml IL-4 with or without 20% (vol/vol) of 
the culture supernatant of the A375mel cells prepared in Fig. 3. (a) Half 
of the media, cytokines, and the culture supernatant was changed 
every 2 d. On day 5 of the culture, LPS was added at 100 ng/ml. After 
15 h, the culture supernatants were collected and subjected to ELISA of 
IL-12 and TNF-α.1656  BRAF–MAPK-MEDIATED CANCER-IMMUNE EVASION | Sumimoto et al.
Lentivirus-mediated RNAi. HIV lentiviral vectors for shRNA expression 
were prepared as described previously (11). The shRNA target sequences 
were as follows: for mutated BRAF (V600E), (BRAF#1′) G C  T  A  C  A  G  A  G  A-
A  A  T  C  T  C  G  A  T  ; for STAT3, (STAT3#4) A T  A  G  G  A  A  G  G  T  T  T  A  A  G  G  A  G  A  ; 
and for fi  refl  y luciferase (control shRNA, GL3B) G  T  G  C  G  C  T  G  C  T  G  G  T-
G  C  C  A  A  C  . The construction of an HIV-U6-BRAF/STAT3-GFP vector 
with the tandem arranged two shRNA units was similar with the previous 
report (18).
5–6 d after the transduction, the melanoma cells were analyzed for the 
cytokine production and signaling molecules by ELISA and Western blot 
analysis, and the equivalent transduction was confi  rmed by the GFP expres-
sion from the vector (11) by fl  ow cytometry analysis.
EMSA. 5 μg of nuclear extracts was mixed with 5× binding buff  er, poly d 
(I-C), and [γ32P] ATP-labeled STAT3 double-stranded oligonucleotide probe 
with or without either unlabeled wild (5′-G  A  T  C  C  T  T  C  T  G  G  G  A  A  T  T  C  C  T-
A  G  A  T  C  -3′) or mutant (5′-G  A  T  C  C  T  T  C  T  G  G  G  C  C  G  T  C  C  T  A  G  A  T  C  -3′) 
STAT3 double-stranded oligonucleotide probe. The mixed samples were 
then subjected to electrophoresis in a 6.0% polyacrylamide gel. The radioac-
tivity on the gel was developed by using a BAS imaging system (FUJI).
Western blot. Anti-BRAF (Santa Cruz Biotechnology, Inc.), anti-ERK2 
(Santa Cruz Biotechnology, Inc.), anti-ppERK1/2 (Cell Signaling), anti-
STAT3 (Cell Signaling), anti–phospho-STAT3 (Ser727; Cell Signaling), 
and anti–phospho-STAT3 (Tyr705; Cell Signaling) antibodies were used for 
the fi  rst antibody. A horseradish peroxidase–conjugated anti-IgG antibody 
was used for the second antibody.
STAT3 reporter assay. 0.4 μg pSTAT3-TA-Luc (CLONTECH Labora-
tories, Inc.) with 0.4 μg pRL-SV40 were cotransfected to 2–4 × 105 mela-
noma cells with or without BRAF RNAi. 24 h after the transfection, the 
cells were analyzed for the fi  refl  y and renilla luciferase activity. Each fi  refl  y 
luciferase activity was normalized to renilla luciferase activity.
DC induction. Human CD14+ monocytes isolated by using CD14 Micro-
Beads (Miltenyi Biotec) were cultured in RPMI 1640 medium supple-
mented with 10% FBS, 100 ng/ml GM-CSF, and 50 ng/ml IL-4 with or 
without the conditioned medium of the A375mel cells transduced with HIV 
lentiviral vectors. On day 5 of the culture, LPS was added at 100 ng/ml for 
the maturation of DCs, and on day 6, the culture supernatant was collected 
and analyzed for ELISA.
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